Fruquintinib
- Generic Name
- Fruquintinib
- Brand Names
- Fruzaqla
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19N3O5
- CAS Number
- 1194506-26-7
- Unique Ingredient Identifier
- 49DXG3M5ZW
Overview
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.
Background
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.
Indication
本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Fruzaqla
Manufacturer:Takeda Pharmaceuticals America, Inc.
Route:ORAL
Strength:5 mg in 1 1
Approved: 2023/11/14
NDC:63020-225
Fruzaqla
Manufacturer:Takeda Pharmaceuticals America, Inc.
Route:ORAL
Strength:1 mg in 1 1
Approved: 2023/11/14
NDC:63020-210
Singapore Approved Products
FRUZAQLA CAPSULE 5MG
Manufacturer:STA Pharmaceutical Switzerland SA
Form:CAPSULE
Strength:5mg
Online:Yes
Approved: 2024/10/17
Approval:SIN17113P
FRUZAQLA CAPSULE 1MG
Manufacturer:STA Pharmaceutical Switzerland SA
Form:CAPSULE
Strength:1mg
Online:Yes
Approved: 2024/10/17
Approval:SIN17114P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath